Funding for this research was provided by:
National Institute of Child Health and Human Development (HD036071, HD02274, HD103526)
National Institute of Mental Health (MH078041)
National Institute of Neurological Disorders and Stroke (NS110100)
National Institute on Aging (AG032115)
Received: 22 October 2021
Accepted: 14 March 2022
First Online: 23 March 2022
: This study was approved by the Institutional Review Board (IRB) at UC Davis (ID# 473010), and all participants gave informed consent.
: Not applicable.
: Dr Hessl has received funding from the following, all of which is directed to UC Davis, in support of fragile X syndrome treatment programs, and he receives no personal funds and has no relevant financial interest in any of the commercial entities listed: Autifony, Ovid, Tetra, Healx, and Zynerba pharmaceutical companies to consult on outcome measures and clinical trial design. RJH has received funding from Zynerba and the Azrieli foundation for treatment studies in Fragile X syndrome and unrelated to this study.